Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
West Nile Virus Infections - Overview
West Nile Virus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
West Nile Virus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
West Nile Virus Infections - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
CEL-SCI Corp
Emergex Vaccines Ltd
Enid Therapeutics LLC
Fab’entech SA
Hawaii Biotech Inc
Imutex Ltd
Kineta Inc
jit Technologies Inc
Plex Pharmaceuticals Inc
West Nile Virus Infections - Drug Profiles
AGS-v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGS-v PLUS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alferon LDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotide for West Nile Virus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BG-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBV-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HydroVax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-n3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Flavivirus Serine Protease for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tatbeclin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WNV-86 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile Virus Infections - Dormant Projects
West Nile Virus Infections - Product Development Milestones
Featured News & Press Releases
Nov 20, 2018: Vanderbilt discovery could neutralize West Nile virus
Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate
Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Are
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for West Nile Virus Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for West Nile Virus Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: West Nile Virus Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
Table 11: West Nile Virus Infections - Pipeline by CEL-SCI Corp, H2 2019
Table 12: West Nile Virus Infections - Pipeline by Emergex Vaccines Ltd, H2 2019
Table 13: West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC, H2 2019
Table 14: West Nile Virus Infections - Pipeline by Fab’entech SA, H2 2019
Table 15: West Nile Virus Infections - Pipeline by Hawaii Biotech Inc, H2 2019
Table 16: West Nile Virus Infections - Pipeline by Imutex Ltd, H2 2019
Table 17: West Nile Virus Infections - Pipeline by Kineta Inc, H2 2019
Table 18: West Nile Virus Infections - Pipeline by Najit Technologies Inc, H2 2019
Table 19: West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2019
Table 20: West Nile Virus Infections - Dormant Projects, H2 2019
Table 21: West Nile Virus Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019